Industry · July 24, 2026

When Botox Stops Working: Resistance, Tolerance, and the Dosing Habits Behind It

Patients who have had neuromodulator injections for years eventually report the same thing: it does not last like it used to. Some of that is real immune resistance, in which the body builds antibodies that neutralize the toxin before it can work. Most of it is not. It is dosing drift, injector turnover, unrealistic memory of the first result, and a treatment schedule that quietly trained the immune system to notice the drug. Here is what the evidence says about botulinum toxin resistance, how often it actually happens, and what a competent injector does about it.

By The Editorial Desk

7 min read

Ask any injector who has been practicing for more than a decade and they will tell you about the conversation. A patient who has been coming in three or four times a year since her early thirties sits down and says the same sentence, in the same slightly accusatory tone: it does not work like it used to. Sometimes she is right and something measurable has changed in her immune system. Far more often she is right about the observation and wrong about the cause. Botulinum toxin resistance is real, it is documented, and it is rare enough that most patients who believe they have it do not. The trouble is that the aesthetics industry has no financial incentive to sort the two apart, because the reflex answer to a weak result, which is more units more often, happens to be the single behavior most likely to cause the real version of the problem.

True resistance means neutralizing antibodies, and it is uncommon

The short answer: genuine botulinum toxin resistance happens when the immune system produces neutralizing antibodies against the toxin's active component, and published estimates in aesthetic patients put it in the low single-digit percentages, not the double digits patients assume.

Botulinum toxin type A is a bacterial protein. Inject any foreign protein repeatedly and the immune system may eventually learn to recognize it. When the antibodies produced are neutralizing, meaning they bind the 150 kilodalton core neurotoxin and block it from reaching the nerve terminal, the injection simply does not do anything. This is well documented in the therapeutic neurology literature, where patients treated for cervical dystonia receive doses many times larger than any cosmetic patient and secondary non-response is a recognized clinical problem. In aesthetic practice the doses are far smaller and true immunologic non-response is correspondingly less common. Review work in the aesthetic and neurology literature generally places clinically meaningful neutralizing antibody formation in cosmetic patients somewhere around or below the low single digits, and complete non-response is rarer still. The important distinction, and the one almost never explained in a med spa, is that having detectable antibodies is not the same as having a failed treatment. Plenty of patients carry antibodies and still respond fine.

Most "resistance" is not resistance at all

The short answer: the far more common explanations are dose, dilution, injector technique, product switching, muscle mass, and a memory of the first result that no subsequent treatment can match.

Before anyone should discuss immunology, five ordinary explanations need to be ruled out. First, dose. Units get quietly trimmed as pricing pressure rises or as an injector tries to keep a patient in a comfortable price band, and a glabellar complex that once got a standard twenty units now gets twelve. Second, product. The available type A products are not interchangeable unit for unit, and a patient switched from one brand to another at the same number of units may be receiving a meaningfully different biological dose. Third, technique. Placement and depth matter enormously, and an injector who trained on a different pattern will produce a different result with identical product. Fourth, anatomy. Muscle hypertrophy is real, and a patient who has been treated for years may have shifted her expressive habit to muscles nobody is treating, so the frown reappears from a new direction. Fifth, and most underestimated, memory. The first treatment on a never-treated face produces the largest visible delta anyone will ever get, and every treatment after that is compared against a baseline that no longer exists.

"
Having antibodies is not the same as having a failed treatment. The far more common cause of a disappointing result is that the units went down, the product changed, or the patient is comparing everything to the first time.
"

The dosing habits that raise the risk

The short answer: high doses, short intervals, and frequent touch-up injections are the pattern most consistently associated with antibody formation, which means the industry's most patient-pleasing behaviors are also its riskiest.

The immunology here is not controversial. Antigen exposure that is large, frequent, and repeated is the setup most likely to provoke an antibody response, and the neurology literature has associated exactly that pattern with secondary non-response. Translated into aesthetic terms, the risk factors are treatment intervals shorter than roughly three months, escalating unit counts, and the two-week "top up" that has become a normal part of the injectable business. Product formulation also enters the conversation. Conventional type A products include accessory complexing proteins alongside the core neurotoxin, while one formulation on the market is a purified toxin without those complexing proteins, and its manufacturer has argued this reduces immunogenic load. The independent evidence supporting a clinically meaningful advantage is thinner than the marketing suggests, and a careful injector treats it as a reasonable option for a suspected resistance case rather than a proven solution for everyone. What is not in dispute is the behavioral half: injecting more, sooner, more often, is the pattern to avoid, and it is precisely what a patient chasing a fading result tends to demand.

The patient-framing test: If your injections have stopped working, do not open with "I think I am resistant." Open with three questions that force the actual variables into the open. First: "What was my exact unit count and product at each of my last four visits?" A practice that cannot produce that record is not in a position to diagnose anything, and the answer very often reveals a dose that drifted down. Second: "How far apart have my treatments been?" If the answer includes intervals under three months or routine two-week touch-ups, the fix is a longer schedule before anything else. Third: "Can we test one muscle group at a full standard dose and photograph it at two weeks?" A frontalis or glabellar test dose with proper before-and-after documentation is how you distinguish true non-response from under-dosing, and any injector who prefers to skip that step and simply sell you a different brand is guessing with your money.

How a competent practice actually works it up

The short answer: the workup is a full-dose test injection in a single muscle group with photographic documentation at two weeks, not an antibody blood test, because commercial antibody assays are not a routine or reliable clinical tool in aesthetics.

Patients often expect a lab test, and there is no useful one available in an ordinary cosmetic setting. Research assays that measure neutralizing activity exist but are not standard commercial diagnostics, and detecting antibodies would not by itself prove clinical non-response. The practical test is functional. A careful injector re-treats a single well-defined area at a full standard dose, on a clean interval, with standardized photographs at rest and in animation before treatment and again at roughly two weeks, which is when the peak effect should be visible. If that muscle does not move, the finding is meaningful. If it moves less than it used to but clearly moves, the problem was almost certainly dosing or technique. The other functional check available in a clinical setting is the frontalis or brow test, in which a small standard dose is placed in a muscle whose paralysis is unmistakable on photograph. The whole point is to convert a subjective complaint into an observable result, which is the step most volume-driven practices skip.

What to do if the result is real

The short answer: the response to genuine non-response is a treatment holiday, a review of product and dose, consideration of a different serotype or formulation, and honest acknowledgment that some patients will need to rely on other modalities.

If a full-dose test injection genuinely fails, the first move is time. Antibody titers can decline over months to years without exposure, and a deliberate pause, often measured in a year or more rather than weeks, gives the immune response a chance to wane. Second is a formulation review, including a trial of a purified toxin without complexing proteins, understanding that this is a reasonable attempt rather than a guarantee. Third, in some clinical contexts, is a different serotype, though the type B product available is used mainly in therapeutic neurology and has a different side effect profile that makes it a poor routine cosmetic substitute. Fourth is the answer nobody sells: not every dynamic line has to be treated with a neuromodulator. Resurfacing, careful filler, energy-based treatment, and in some cases surgery address the etched-in component of expression lines that toxin was never going to erase anyway. A patient who has been treated for fifteen years often has static lines that need a different tool regardless of whether the toxin still works.

The honest summary

Botulinum toxin resistance deserves to be taken seriously and it deserves to be diagnosed properly, and the aesthetics industry does almost neither. True neutralizing antibody formation is a documented phenomenon, well described in the neurology literature at therapeutic doses, and uncommon at the doses used cosmetically. Most patients who say their injections stopped working are describing something real that has an ordinary explanation: units that drifted down, a product swap treated as unit-for-unit equivalent, a new injector with a different pattern, a shifting expressive habit, or a comparison against a first-ever result that cannot be reproduced. The genuinely useful insight is that the standard commercial response to a weak result, which is to inject more units at shorter intervals with a no-charge touch-up two weeks later, is exactly the exposure pattern the immunology literature associates with antibody formation. In other words, the business practice designed to keep patients happy is the one most likely to create the problem they fear. For a patient, the practical protocol is unglamorous. Get your dosing history in writing, stretch the interval to at least three months, refuse routine touch-ups, and insist on a documented full-dose test in one muscle group with photographs before anyone diagnoses you with anything. For an injector, the discipline is the same one that shows up everywhere else in aesthetic medicine: treat less often, document more carefully, and stop selling a second syringe as the answer to the first one underperforming.

All dispatches